ADCs Raw Materials MonoMethyl Dolastatin 10/MMAD for Research Only

ADCs Raw Materials MonoMethyl Dolastatin 10/MMAD for Research Only

Synonyms:DeMethyldolastatin 10;MMAD;MonoMethyl Dolastatin 10;MonoMethylauristatin D;(S)-N-((3R,4S,5S)-3-methoxy-1-((S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((S)-2-phenyl-1-(thiazol-2-yl)ethyl)amino)propyl)pyrrolidin-1-yl)-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide

CAS:203849-91-6

MF:C41H66N6O6S

General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

 

MMAD is a highly potent inhibitor of tubulin . MMAD is one of the auristatins, which are used as the drugs of antibody drug conjugates (ADCs). In ADCs, the therapeutic compounds and the high selectivity of antibodies are combined by the linkers. By taking advantage of antigen-selectivity of MAbs, it can deliver these cytotoxic drugs to antigen-expressing tumor cells, thus increasing both the efficacy and safety of therapy. As a payload of ADCs, MMAD is used to target the tubulin of the tumor cells. It can interfere with tubulin polymerization and induce rapid cell death at low picomolar concentrations [1]. Additionally, MMAD is reported to be used in the production of site-specific antibody drug conjugates (NDCs). In the NDCs, MMAD is combined with anti-5T4 antibody or anti-Her2 antibody. It is shown that the NDCs demonstrate better efficacy and pharmacokinetics .

MMAD is a highly potent inhibitor of tubulin.MMAD is one of the auristatins, which are used as the drugs of antibody drug conjugates (ADCs). In ADCs, the therapeutic compounds and the high selectivity of antibodies are combined by the linkers. By taking advantage of antigen-selectivity of MAbs, it can deliver these cytotoxic drugs to antigen-expressing tumor cells, thus increasing both the efficacy and safety of therapy. As a payload of ADCs, MMAD is used to target the tubulin of the tumor cells. It can interfere with tubulin polymerization and induce rapid cell death at low picomolar concentrations .Additionally, MMAD is reported to be used in the production of site-specific antibody drug conjugates (NDCs). In the NDCs, MMAD is combined with anti-5T4 antibody or anti-Her2 antibody. It is shown that the NDCs demonstrate better efficacy and pharmacokinetics .

Monomethyl auristatin E (MMAE, vedotin) is a very potent antimitotic agent that inhibits cell division by blocking the polymerisation of tubulin.  The family of auristatins are synthetic analogues of the antineoplastic natural product Dolastatin 10,  ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody-drug conjugates. 

Monomethyl auristatin E or MMAE is 100-1000 times more potent than doxorubicin (Adriamycin/Rubex) and cannot be used as a drug itself. However, as part of an antibody-drug conjugate or ADC, MMAE is linked to a monoclonal antibody (mAb) that recognizes a specific marker expression in cancer cells and directs MMAE to a specific, targeted cancer cell.

MonoMethyl Dolastatin 10	203849-91-6
MMAE	474645-27-7
MMAF	745017-94-1
DM1	139504-50-0
Vandetanib	443913-73-3
nintedanib	656247-17-5
PF06463922	1454846-35-5
AZD6244/ Selumetinib	606143-52-6
INCB28060	606143-52-6
BKM120	944396-07-0
AZD3759	1626387-80-1
AP26113	1197958-12-5
linifanib/ABT-869	796967-16-3
AZD9291	1421373-66-1
WZ4002	1213269-23-8
dacomitinib	1110813-31-4
crizotinib	877399-52-5
Regorafenib hydrate	1019206-88-2
regorafenib	755037-03-7
Imatinib Mesylate	220127-57-1